HEIDELBERG PHARMA AG (HPHA.DE) Fundamental Analysis & Valuation

FRA:HPHA • DE000A11QVV0

Current stock price

2.85 EUR
-0.08 (-2.73%)
Last:

This HPHA.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. HPHA.DE Profitability Analysis

1.1 Basic Checks

  • HPHA had negative earnings in the past year.
  • HPHA had a negative operating cash flow in the past year.
  • HPHA had negative earnings in each of the past 5 years.
  • In the past 5 years HPHA always reported negative operating cash flow.
HPHA.DE Yearly Net Income VS EBIT VS OCF VS FCFHPHA.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • HPHA has a worse Return On Assets (-48.43%) than 62.03% of its industry peers.
  • HPHA has a Return On Equity (-248.59%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -48.43%
ROE -248.59%
ROIC N/A
ROA(3y)-26.81%
ROA(5y)-58.88%
ROE(3y)-44.53%
ROE(5y)-133.28%
ROIC(3y)N/A
ROIC(5y)N/A
HPHA.DE Yearly ROA, ROE, ROICHPHA.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • HPHA's Gross Margin of 84.66% is fine compared to the rest of the industry. HPHA outperforms 73.42% of its industry peers.
  • HPHA's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for HPHA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y8.66%
HPHA.DE Yearly Profit, Operating, Gross MarginsHPHA.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. HPHA.DE Health Analysis

2.1 Basic Checks

  • HPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for HPHA remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, HPHA has more shares outstanding
  • The debt/assets ratio for HPHA is higher compared to a year ago.
HPHA.DE Yearly Shares OutstandingHPHA.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
HPHA.DE Yearly Total Debt VS Total AssetsHPHA.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • HPHA has an Altman-Z score of -7.80. This is a bad value and indicates that HPHA is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of HPHA (-7.80) is worse than 79.75% of its industry peers.
  • A Debt/Equity ratio of 3.47 is on the high side and indicates that HPHA has dependencies on debt financing.
  • HPHA has a Debt to Equity ratio of 3.47. This is in the lower half of the industry: HPHA underperforms 62.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.47
Debt/FCF N/A
Altman-Z -7.8
ROIC/WACCN/A
WACC7.13%
HPHA.DE Yearly LT Debt VS Equity VS FCFHPHA.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 5.85 indicates that HPHA has no problem at all paying its short term obligations.
  • HPHA has a Current ratio of 5.85. This is amongst the best in the industry. HPHA outperforms 88.61% of its industry peers.
  • A Quick Ratio of 3.55 indicates that HPHA has no problem at all paying its short term obligations.
  • HPHA's Quick ratio of 3.55 is fine compared to the rest of the industry. HPHA outperforms 74.68% of its industry peers.
Industry RankSector Rank
Current Ratio 5.85
Quick Ratio 3.55
HPHA.DE Yearly Current Assets VS Current LiabilitesHPHA.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. HPHA.DE Growth Analysis

3.1 Past

  • The earnings per share for HPHA have decreased strongly by -35.76% in the last year.
  • Looking at the last year, HPHA shows a very negative growth in Revenue. The Revenue has decreased by -64.15% in the last year.
  • Measured over the past years, HPHA shows a decrease in Revenue. The Revenue has been decreasing by -1.29% on average per year.
EPS 1Y (TTM)-35.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.71%
Revenue 1Y (TTM)-64.15%
Revenue growth 3Y57.6%
Revenue growth 5Y-1.29%
Sales Q2Q%-96.05%

3.2 Future

  • Based on estimates for the next years, HPHA will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.35% on average per year.
  • Based on estimates for the next years, HPHA will show a small growth in Revenue. The Revenue will grow by 6.54% on average per year.
EPS Next Y-44.19%
EPS Next 2Y15.13%
EPS Next 3Y15.35%
EPS Next 5YN/A
Revenue Next Year-16.28%
Revenue Next 2Y-3.55%
Revenue Next 3Y6.54%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HPHA.DE Yearly Revenue VS EstimatesHPHA.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M 20M
HPHA.DE Yearly EPS VS EstimatesHPHA.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

0

4. HPHA.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • HPHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HPHA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HPHA.DE Price Earnings VS Forward Price EarningsHPHA.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HPHA.DE Per share dataHPHA.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • HPHA's earnings are expected to grow with 15.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.13%
EPS Next 3Y15.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HPHA.DE Dividend Analysis

5.1 Amount

  • HPHA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HPHA.DE Fundamentals: All Metrics, Ratios and Statistics

HEIDELBERG PHARMA AG

FRA:HPHA (3/26/2026, 9:57:53 AM)

2.85

-0.08 (-2.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-09
Earnings (Next)N/A
Inst Owners2.03%
Inst Owner ChangeN/A
Ins Owners44%
Ins Owner ChangeN/A
Market Cap133.32M
Revenue(TTM)3.04M
Net Income(TTM)-26.18M
Analysts82.5
Price Target5.61 (96.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.22%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 43.89
P/FCF N/A
P/OCF N/A
P/B 12.66
P/tB 78.75
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0.06
BVpS0.23
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.43%
ROE -248.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.66%
FCFM N/A
ROA(3y)-26.81%
ROA(5y)-58.88%
ROE(3y)-44.53%
ROE(5y)-133.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y8.66%
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 3.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.98%
Cap/Sales 11.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.85
Quick Ratio 3.55
Altman-Z -7.8
F-Score1
WACC7.13%
ROIC/WACCN/A
Cap/Depr(3y)81.7%
Cap/Depr(5y)122.7%
Cap/Sales(3y)6.67%
Cap/Sales(5y)23.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.71%
EPS Next Y-44.19%
EPS Next 2Y15.13%
EPS Next 3Y15.35%
EPS Next 5YN/A
Revenue 1Y (TTM)-64.15%
Revenue growth 3Y57.6%
Revenue growth 5Y-1.29%
Sales Q2Q%-96.05%
Revenue Next Year-16.28%
Revenue Next 2Y-3.55%
Revenue Next 3Y6.54%
Revenue Next 5YN/A
EBIT growth 1Y-33.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-46.94%
EBIT Next 3Y16.64%
EBIT Next 5YN/A
FCF growth 1Y9.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.32%
OCF growth 3YN/A
OCF growth 5YN/A

HEIDELBERG PHARMA AG / HPHA.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for HEIDELBERG PHARMA AG?

ChartMill assigns a fundamental rating of 2 / 10 to HPHA.DE.


What is the valuation status of HEIDELBERG PHARMA AG (HPHA.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to HEIDELBERG PHARMA AG (HPHA.DE). This can be considered as Overvalued.


What is the profitability of HPHA stock?

HEIDELBERG PHARMA AG (HPHA.DE) has a profitability rating of 1 / 10.


What is the financial health of HEIDELBERG PHARMA AG (HPHA.DE) stock?

The financial health rating of HEIDELBERG PHARMA AG (HPHA.DE) is 3 / 10.


Can you provide the expected EPS growth for HPHA stock?

The Earnings per Share (EPS) of HEIDELBERG PHARMA AG (HPHA.DE) is expected to decline by -44.19% in the next year.